Support Center

Cancer EKG

Cardio-Oncology

Cardiovascular disease is the second leading cause of morbidity and mortality after secondary malignancies among cancer survivors. 

Cardiotoxic Effects
While modern cancer treatments have led to improved survival rates among the most common types of cancers, various treatments ranging from traditional cytotoxic agents and radiology, to newly developed immunotherapies and anti-angiogenics have been linked to adverse cardiac events. Some common conditions linked to cancer treatments include hypertension, arrythmias, heart failure, QT prolongation, and other cardiomyopathies. For example, the anti-angiogenic VEGF receptor (VEGFR) inhibitors used to treat solid and hematologic malignancies, cause hypertension in 15 – 60% of occurrences and increases the patients risk of heart failure.1  Identified cardiac adverse effects has brought about the demand to do more safety testing to ensure treatments do not cause cardiotoxicity. Researchers are not only using cardiovascular safety assessments in animal models to help validate or rule out compounds earlier in preclinical studies, but they are also reevaluating current treatments that are already on the market. 

Animal Models and Endpoints
Researchers studying cardiovascular responses and drug safety of potential and current cancer treatments use a variety of animal models, including rodents, rabbits, dogs and non-human primates. Since a majority of adverse cardiac effects do not appear for 10 - 15 years after treatment, animals are helpful in determining what long-term effects will occur due to their shorter life spans. Long-term studies with continuous cardiovascular data can improve understanding of cardiac function post treatment, facilitating earlier interventions and improved quality of life. Primary cardiovascular endpoints include systolic and diastolic arterial pressure, left ventricular pressure, heart rate, and electrocardiogram.  Additionally, if warranted, further evaluation of the following endpoints may need to be studied including cardiac output, ventricular contractility, vascular resistance, and/or the effects of endogenous and/or exogenous substances on the cardiovascular responses.



1,827
safety pharmacology and toxicology
publications citing DSI in 
Google Scholar

hipertension-arterial



iStock-940800024


Why Choose DSI?

  • Global leader in preclinical cardiovascular monitoring solutions
  • Over 30 years of providing researchers with essential tools to measure cardiovascular endpoints in both Safety Pharmacology and Toxicology studies
  • GLP-compliant systems for acquisition and reporting
  • Products that provide the sensitivity to detect, or more importantly rule-out, unwanted drug effects within the constraints of protecting the welfare of the animal subjects and reasonable drug development costs
  • Products that allow the animals to move freely in an unrestrained, stress-free environment, ensuring accurate data collecting with increased translatability
  • Software that researchers can rely on to confidently collect, accurately analyze, and quickly summarize study data
  • Software modules that include automated arrhythmia detection, ECG analysis, left ventricular pressure analysis,blood pressure analysis, blood pressure respiration, cardiac volume, PV loop, blood flow, and many more 

DSI Cardiovascular Safety Research Tools

DSI telemetry is completely implantable and designed for acquiring physiologic data from conscious, freely moving laboratory animals, reducing animal stress and ensuring the most reliable cardiovascular and/or other biopotential data. We offer a comprehensive line of telemetry implants capable of simultaneously measuring pressure, bioelectrical, temperature and activity endpoints in species ranging from mice to non-human primate. 



Cardiovascular Telemetry Implants for Mouse (Miniature) Models
PhystioTel implants are designed for use in mice (including transgenic), hamsters, juvenile rats and other species of similar size. 


PAC10

HDX10

     HDx11



Cardiovascular Telemetry Implants for Small Animal Models
PhystioTel implants are designed for use in rats, guinea pigs, rabbits, and species of similar size. 




Cardiovascular Telemetry Implants for Large Animal Models
Designed for use in canines, non-human primates, swine, sheep, and species of similar size. Our large animal PhysioTel digital implants give researchers the power of acquiring and analyzing physiologic data from animals in a group housed setting. 

The Power of Ponemah Software
Data collection and analysis for preclinical studies

High resolution image (139 KB)


Easy Experiment Management
  • Save time with intuitive user interface and automated subject setup 
  • Simplify data management with automated file handling
  • Review previous days’ results during acquisition to observe mid-experiment data
  • Visualize sampling configuration and protocols with tabbed sampling layout
  • Use scheduled sampling function to collect periodic data from more subjects at user-defined intervals

Robust Connectivity with 3rd Party Solutions
  • Acquire high quality video recordings in Ponemah's integrated solution with Noldus Media Recorder and synchronize with physiologic signals for better interpretation of your data
  • Import and analyze CNS data - EEG and EMG data with video recordings - in NeuroScore Data Analysis Software 
  • Allow 3rd party applications to view Ponemah derived parameter data with Remote Connection

Flexible Data Analysis
  • Analyze data using time-based averages or on a beat-by-beat basis
  • Immediate results with real-time parameter calculations and trend graph generation
  • Complete control of data analysis with adjustable settings to analyze signals from various species and unique morphologies
  • Automatic export of calculated data to MS Excel® to view and analyze results across multiple days of acquisition
Smart, Powerful Tools
  • Refine data analysis post-acquisition to change how parameters are measured or eliminate signal noise from results
  • Use multiple graph and reporting presentations to view, sort and sync calculated parameters
  • Select data sections to view and report using Data Reduction and Data Parser rules.
  • Receive automated email or text alerts for subject- and system-level conditions

ScheduledSampling

Flexible Licensing Options
  • 3, 6, and 12 month subscription or full purchase options
  • Available for acquisition and post-analysis systems, plus analysis modules
  • Ideal for trials and short-term studies


Learn More About the Power of Ponemah Software


Ponemah Full System Package

System Set Up

Receivers and Transceivers
Telemetry implants broadcast telemetry data via radio frequency signals to the receiver or transceiver located under or near the cage. Multiple options exist and selection depends on study design. 

Communication Manager
The MX2 for small animals or the CLC for large animals manage communication between your chosen implant and Ponemah software. Fully calibrated telemetry data acquisition, optimized to maintain data integrity throughout the system. 

Ambient Pressure Reference
(only needed if monitoring pressure)
The APT-2 is a special type of barometer that measure atmospheric pressure during dynamic corrections via a digital signal to the computer. It is required when measuring pressure via pressure transmitters in order to compensate for the absolute (relative to a vacuum) measurements taken by the transmitters.

Network Hardware
DSI recommends using a dedicated network to permit the hardware to communicate to the computer. A router is used to assign IP addresses and a switch with PoE (Power over Ethernet) is used to power the hardware and allow multiple connections to the network. 

Cardio-Oncology References Citing DSI Technology

Charych, D., Hoch, U., Langowski, J., Lee, S., Addepalli, M., Kirk, P., . . . Doberstein, S. (2016). NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 22(3), 680-90.

Collins, T., Gray, K., Bista, M., Skinner, M., Hardy, C., Wang, H., . . . Harmer, A. R. (2018). Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension. British Journal of Pharmacology, 175(4), 618-630. doi:10.1111/bph.14103

Kim, T., Kim, K., Seo, J., Park, S., & Henry, S. P. (2014). Antisense oligonucleotides on neurobehavior, respiratory, and cardiovascular function, and hERG channel current studies. Journal of Pharmacological and Toxicological Methods, 69(1), 49-60. doi:10.1016/j.vascn.2013.10.005

Miller, Nace, Ayala-Breton C, Steele, Bailey, Peng, & Russell. (2016). Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses. Molecular Therapy, 24(2), 306-317.



References

1 Researchers at AstraZeneca Describe Findings in Hypertension (Quantifying the relationship between inhibition of VEGF receptor 2, drug-induced blood pressure elevation and hypertension). (2018). Health & Medicine Week, 237.